Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Halozyme Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Halozyme Therapeutics, Inc.’s stock price such as:

• Halozyme Therapeutics, Inc.’s current stock price and volume
• Why Halozyme Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for HALO from analysts
• HALO’s stock price momentum as measured by its relative strength

About Halozyme Therapeutics, Inc. (HALO)

Before we jump into Halozyme Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Want to learn more about Halozyme Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Halozyme Therapeutics, Inc.’s stock price was $82.540.

Halozyme Therapeutics, Inc. is down 0.91% from its previous closing price of $83.300.

During the last market session, Halozyme Therapeutics, Inc.’s stock traded between $81.500 and $83.270. Currently, there are approximately 118.14 million shares outstanding for Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc.’s price-earnings (P/E) ratio is currently at 29.3, which is high compared to the Biotechnology industry median of 18.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Halozyme Therapeutics, Inc. Stock Price History

Halozyme Therapeutics, Inc.’s (HALO) price is currently up 5.46% so far this month.

During the month of July, Halozyme Therapeutics, Inc.’s stock price has reached a high of $84.440 and a low of $73.890.

Over the last year, Halozyme Therapeutics, Inc. has hit prices as high as $84.440 and as low as $58.530. Year to date, Halozyme Therapeutics, Inc.’s stock is up 22.64%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Halozyme Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded Halozyme Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Halozyme Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Halozyme Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Halozyme Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Halozyme Therapeutics, Inc. (HALO) by visiting AAII Stock Evaluator.

Relative Price Strength of Halozyme Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Halozyme Therapeutics, Inc. has a weighted four-quarter relative price strength of 9.79%, which translates to a Momentum Score of 81 and is considered to be Very Strong.

Want to learn more about how Halozyme Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Halozyme Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Halozyme Therapeutics, Inc.’s stock price is $82.540, which is down 0.91% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Halozyme Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.